Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Lirilumab (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.
- 01 Feb 2018 Planned initiation date changed from 31 Dec 2017 to 28 Feb 2018.
- 17 Nov 2017 New trial record